SPI-1005 for the Treatment of Meniere's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

August 2, 2022

Primary Completion Date

September 19, 2023

Study Completion Date

July 25, 2024

Conditions
Meniere DiseaseMénière
Interventions
DRUG

Ebselen

Glutathione peroxidase mimetic

DRUG

Placebo

Matching placebo containing excipients

Trial Locations (12)

19144

Thomas Jefferson University, Philadelphia

20037

George Washington University, Washington D.C.

27103

Piedmont Ear, Nose & Throat Associates, Winston-Salem

29425

Medical University of South Carolina, Charleston

33487

ENT and Allergy Associates of Florida, Boca Raton

40207

Advanced ENT & Allergy, Louisville

46202

Indiana University, Indianapolis

66160

Kansas University Medical Center, Kansas City

72205

University of Arkansas for Medical Sciences, Little Rock

90033

University of Southern California, Los Angeles

90057

House Clinic, Los Angeles

95661

Sacramento Ear, Nose, & Throat, Roseville

All Listed Sponsors
lead

Sound Pharmaceuticals, Incorporated

INDUSTRY